Key PointsBristol Myers Squibb’s Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company’s 7% revenue gain to $13.1 billion.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.